Conclusions
The rapid increase in therapeutics targeting complement is already putting pressure on immunology laboratories. This pressure includes the demand for more complement analyses, as well as the need to do that testing rapidly. The clinical immunologist may be increasingly called upon to evaluate what testing will be useful for which new therapeutic and for which disorder. With all the aforementioned complications, complement is a cascade of enzymes and proenzymes, something that coagulation laboratories have been adept at handling for years so clearly the challenge can be met. As more therapeutics are approved and are in use by patients, it is possible testing will be needed to determine the best drug for an individual patient. Individual diversity in complement genetics and component levels can mean that a different drug targeted at different part of the complement cascade may be better for an individual patient, even among those coping with the same disease [67]. In this way the clinical immunology laboratory may be called upon to perform complement testing to aid in the administration of precision medicine.
